Dupixent — Medical Mutual

Initial criteria

• Patient is on therapy with an immune checkpoint inhibitor (e.g., nivolumab, pembrolizumab etc.); AND
• Patient has refractory and severe (grade 3) pruritus

Approval duration

6 months